LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 124

Search options

  1. Book: Catastrophic epilepsies of childhood

    Glauser, Tracy A.

    (Epilepsia ; 45, Suppl. 5)

    2004  

    Author's details guest ed. Tracy A. Glauser
    Series title Epilepsia ; 45, Suppl. 5
    Collection
    Language English
    Size 26 S. : graph. Darst.
    Publisher Blackwell Publ
    Publishing place Malden, MA
    Publishing country United States
    Document type Book
    HBZ-ID HT014114240
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  2. Book: Integrating advances in pediatric epilepsy treatment options into clinical practice

    Glauser, Tracy A.

    (Neurology ; 58,12, Suppl. 7)

    2002  

    Author's details Tracy A. Glauser, guest ed
    Series title Neurology ; 58,12, Suppl. 7
    Collection
    Keywords Epilepsie ; Kinderheilkunde
    Subject Pädiatrie ; Kinder- und Jugendheilkunde ; Kinder- und Jugendmedizin ; Kindermedizin ; Pediatrics ; Fallsucht
    Language English
    Size S24 S. : Ill., graph. Darst.
    Publisher Lippincott, Williams & Wilkins
    Publishing place Hagerstown, Md
    Publishing country United States
    Document type Book
    HBZ-ID HT013394951
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  3. Book: Recent advances in epilepsy

    Glauser, Tracy A.

    (Journal of child neurology ; 17, Suppl. 1)

    2002  

    Author's details guest ed. Tracy A. Glauser
    Series title Journal of child neurology ; 17, Suppl. 1
    Collection
    Keywords Epilepsie
    Subject Fallsucht
    Language English
    Size S93 S. : graph. Darst.
    Publisher Decker
    Publishing place Hamilton, Ontario
    Publishing country Canada
    Document type Book
    HBZ-ID HT013328656
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  4. Article ; Online: The evolving model of pediatric research.

    Cheng, Tina L / Glauser, Tracy A / Reed, Ann

    Pediatric research

    2023  Volume 94, Issue 2, Page(s) 412–415

    MeSH term(s) Child ; Humans ; Pediatrics ; Biomedical Research/trends
    Language English
    Publishing date 2023-07-03
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 4411-8
    ISSN 1530-0447 ; 0031-3998
    ISSN (online) 1530-0447
    ISSN 0031-3998
    DOI 10.1038/s41390-023-02677-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Supporting Treatment Adherence Regimens in young children with epilepsy and their families: Trial design and baseline characteristics.

    Modi, Avani C / Glauser, Tracy A / Guilfoyle, Shanna M

    Contemporary clinical trials

    2020  Volume 90, Page(s) 105959

    Abstract: This article describes the methodology, recruitment, design, and baseline participant characteristics of the Supporting Treatment Adherence Regimens (STAR) trial. STAR is a randomized controlled clinical trial of an education and problem-solving ... ...

    Abstract This article describes the methodology, recruitment, design, and baseline participant characteristics of the Supporting Treatment Adherence Regimens (STAR) trial. STAR is a randomized controlled clinical trial of an education and problem-solving adherence intervention for young children (2-12 years old) with newly diagnosed epilepsy and their families. Using an enrichment design, only participants who demonstrated non-adherence to anti-epileptic drugs within the baseline period were randomized to treatment or control arms. Randomized participants received 8 intervention sessions over a 4-month period and completed three follow-up visits (3, 6, and 12 months following intervention). Two-hundred participants were recruited for the study. The primary outcome was electronically monitored adherence, while secondary and exploratory outcomes included seizure freedom and health-related quality of life. Novel aspects of the trial design (e.g., enrichment, sequential randomization, daily adherence data use), as well as recruitment and retention challenges are discussed.
    MeSH term(s) Child ; Child, Preschool ; Female ; Humans ; Male ; Anticonvulsants/administration & dosage ; Anticonvulsants/therapeutic use ; Epilepsy/drug therapy ; Family ; Medication Adherence/statistics & numerical data ; Patient Education as Topic/organization & administration ; Problem Solving ; Research Design ; Randomized Controlled Trials as Topic
    Chemical Substances Anticonvulsants
    Language English
    Publishing date 2020-02-14
    Publishing country United States
    Document type Clinical Trial Protocol ; Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2182176-8
    ISSN 1559-2030 ; 1551-7144
    ISSN (online) 1559-2030
    ISSN 1551-7144
    DOI 10.1016/j.cct.2020.105959
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Supporting treatment adherence regimens in children with epilepsy: A randomized clinical trial.

    Modi, Avani C / Guilfoyle, Shanna M / Glauser, Tracy A / Mara, Constance A

    Epilepsia

    2021  Volume 62, Issue 7, Page(s) 1643–1655

    Abstract: Objective: This study was undertaken to examine the efficacy of a family-tailored education and problem-solving behavioral intervention, Supporting Treatment Adherence Regimens (STAR), in young children (2-12 years old) with new onset epilepsy compared ... ...

    Abstract Objective: This study was undertaken to examine the efficacy of a family-tailored education and problem-solving behavioral intervention, Supporting Treatment Adherence Regimens (STAR), in young children (2-12 years old) with new onset epilepsy compared to an attention control (i.e., education only [EO]) intervention. Participants randomized to the STAR intervention were hypothesized to demonstrate significantly improved adherence at postintervention and 3-, 6-, and 12-month follow-up visits compared to the EO intervention. Seizure and health-related quality of life (HRQOL) outcomes were also examined.
    Methods: Two hundred children with new onset epilepsy and their caregivers were recruited during routine epilepsy clinic visits. Baseline questionnaires were completed, and electronic adherence monitors were provided. Participants with adherence less than 95% during the run-in period were randomized to either STAR or EO intervention. Active intervention was provided to both groups for 4 months. Questionnaires were completed at conclusion of the active intervention phase and three follow-up time points (3, 6, and 12 months). Group differences in adherence, seizure outcomes, and HRQOL were examined using regression-based analyses of covariance and longitudinal mixed effect linear or logistical models.
    Results: Adherence at 12-month follow-up was significantly different between the STAR (mean = 82.34, SD = 21.29) and EO intervention groups (mean = 61.77, SD = 28.29), with the STAR group demonstrating 20.6% greater adherence (b = 19.11, p = .04, 95% confidence interval = 1.00-37.22, d = .83). No significant differences were found between groups in seizure and HRQOL outcomes.
    Significance: A family-based behavioral adherence intervention demonstrated sustained adherence improvements 1 year following epilepsy diagnosis compared to an epilepsy-specific education intervention. STAR is an efficacious adherence intervention that can easily be implemented into routine epilepsy care.
    MeSH term(s) Anticonvulsants/therapeutic use ; Caregivers ; Child ; Child, Preschool ; Epilepsy/drug therapy ; Female ; Follow-Up Studies ; Humans ; Male ; Medication Adherence/statistics & numerical data ; Patient Education as Topic ; Quality of Life ; Seizures/drug therapy ; Seizures/epidemiology ; Surveys and Questionnaires
    Chemical Substances Anticonvulsants
    Language English
    Publishing date 2021-05-12
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural
    ZDB-ID 216382-2
    ISSN 1528-1167 ; 0013-9580
    ISSN (online) 1528-1167
    ISSN 0013-9580
    DOI 10.1111/epi.16921
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Developmental Epidemiology of Pediatric Anxiety Disorders.

    Warner, Emily N / Ammerman, Robert T / Glauser, Tracy A / Pestian, John P / Agasthya, Greeshma / Strawn, Jeffrey R

    Child and adolescent psychiatric clinics of North America

    2023  Volume 32, Issue 3, Page(s) 511–530

    Abstract: This review summarizes the developmental epidemiology of childhood and adolescent anxiety disorders. It discusses the coronavirus disease of 2019 (COVID-19) pandemic, sex differences, longitudinal course, and stability of anxiety disorders in addition to ...

    Abstract This review summarizes the developmental epidemiology of childhood and adolescent anxiety disorders. It discusses the coronavirus disease of 2019 (COVID-19) pandemic, sex differences, longitudinal course, and stability of anxiety disorders in addition to recurrence and remission. The trajectory of anxiety disorders-whether homotypic (ie, the same anxiety disorder persists over time) or heterotypic (ie, an anxiety disorder shifts to a different diagnosis over time) is discussed with regard to social, generalized, and separation anxiety disorders as well as specific phobia, and panic disorder. Finally, strategies for early recognition, prevention, and treatment of disorders are discussed.
    MeSH term(s) Adolescent ; Humans ; Female ; Male ; Child ; COVID-19/epidemiology ; Anxiety Disorders/epidemiology ; Anxiety Disorders/therapy ; Anxiety Disorders/diagnosis ; Phobic Disorders/diagnosis ; Phobic Disorders/epidemiology ; Phobic Disorders/therapy ; Panic Disorder/diagnosis ; Panic Disorder/epidemiology ; Anxiety, Separation/diagnosis
    Language English
    Publishing date 2023-03-21
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1313996-4
    ISSN 1558-0490 ; 1056-4993
    ISSN (online) 1558-0490
    ISSN 1056-4993
    DOI 10.1016/j.chc.2023.02.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Early Identification of Candidates for Epilepsy Surgery: A Multicenter, Machine Learning, Prospective Validation Study.

    Wissel, Benjamin D / Greiner, Hansel M / Glauser, Tracy A / Pestian, John P / Ficker, David M / Cavitt, Jennifer L / Estofan, Leonel / Holland-Bouley, Katherine D / Mangano, Francesco T / Szczesniak, Rhonda D / Dexheimer, Judith W

    Neurology

    2024  Volume 102, Issue 4, Page(s) e208048

    Abstract: Background and objectives: Epilepsy surgery is often delayed. We previously developed machine learning (ML) models to identify candidates for resective epilepsy surgery earlier in the disease course. In this study, we report the prospective validation.!# ...

    Abstract Background and objectives: Epilepsy surgery is often delayed. We previously developed machine learning (ML) models to identify candidates for resective epilepsy surgery earlier in the disease course. In this study, we report the prospective validation.
    Methods: In this multicenter, prospective, longitudinal cohort study, random forest models were validated at a pediatric epilepsy center consisting of 2 hospitals and 14 outpatient neurology clinic sites and an adult epilepsy center with 2 hospitals and 27 outpatient neurology clinic sites. The models used neurology visit notes, EEG and MRI reports, visit patterns, hospitalizations, and medication, laboratory, and procedure orders to identify candidates for surgery. The models were trained on historical data up to May 10, 2019. Patients with an ICD-10 diagnosis of epilepsy who visited from May 11, 2019, to May 10, 2020, were screened by the algorithm and assigned surgical candidacy scores. The primary outcome was area under the curve (AUC), which was calculated by comparing scores from patients who underwent epilepsy surgery before November 10, 2020, against scores from nonsurgical patients. Nonsurgical patients' charts were reviewed to determine whether patients with high scores were more likely to be missed surgical candidates. Delay to surgery was defined as the time between the first visit that a surgical candidate was identified by the algorithm and the date of the surgery.
    Results: A total of 5,285 pediatric and 5,782 adult patients were included to train the ML algorithms. During the study period, 41 children and 23 adults underwent resective epilepsy surgery. In the pediatric cohort, AUC was 0.91 (95% CI 0.87-0.94), positive predictive value (PPV) was 0.08 (0.05-0.10), and negative predictive value (NPV) was 1.00 (0.99-1.00). In the adult cohort, AUC was 0.91 (0.86-0.97), PPV was 0.07 (0.04-0.11), and NPV was 1.00 (0.99-1.00). The models first identified patients at a median of 2.1 years (interquartile range [IQR]: 1.2-4.9 years, maximum: 11.1 years) before their surgery and 1.3 years (IQR: 0.3-4.0 years, maximum: 10.1 years) before their presurgical evaluations.
    Discussion: ML algorithms can identify surgical candidates earlier in the disease course. Even at specialized epilepsy centers, there is room to shorten the time to surgery.
    Classification of evidence: This study provides Class II evidence that a machine learning algorithm can accurately distinguish patients with epilepsy who require resective surgery from those who do not.
    MeSH term(s) Adult ; Humans ; Child ; Longitudinal Studies ; Epilepsy/diagnosis ; Epilepsy/surgery ; Prospective Studies ; Cohort Studies ; Machine Learning ; Retrospective Studies
    Language English
    Publishing date 2024-02-05
    Publishing country United States
    Document type Multicenter Study ; Journal Article
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/WNL.0000000000208048
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Implementation of CYP2D6-guided opioid therapy at Cincinnati Children's Hospital Medical Center.

    Ramsey, Laura B / Prows, Cynthia A / Chidambaran, Vidya / Sadhasivam, Senthilkumar / Quinn, Charles T / Teusink-Cross, Ashley / Tang Girdwood, Sonya / Dawson, D Brian / Vinks, Alexander A / Glauser, Tracy A

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

    2024  Volume 80, Issue 13, Page(s) 852–859

    Abstract: Purpose: We describe the implementation of CYP2D6-focused pharmacogenetic testing to guide opioid prescribing in a quaternary care, nonprofit pediatric academic medical center.: Summary: Children are often prescribed oral opioids after surgeries, for ...

    Abstract Purpose: We describe the implementation of CYP2D6-focused pharmacogenetic testing to guide opioid prescribing in a quaternary care, nonprofit pediatric academic medical center.
    Summary: Children are often prescribed oral opioids after surgeries, for cancer pain, and occasionally for chronic pain. In 2004, Cincinnati Children's Hospital Medical Center implemented pharmacogenetic testing for CYP2D6 metabolism phenotype to inform codeine prescribing. The test and reports were updated to align with changes over time in the testing platform, the interpretation of genotype to phenotype, the electronic health record, and Food and Drug Administration (FDA) guidance. The use of the test increased when a research project required testing and decreased as prescribing of oxycodone increased due to FDA warnings about codeine. Education about the opioid-focused pharmacogenetic test was provided to prescribers (eg, the pain and sickle cell teams) as well as patients and families. Education and electronic health record capability increased provider compliance with genotype-guided postsurgical prescribing of oxycodone, although there was a perceived lack of utility for oxycodone prescribing.
    Conclusion: The implementation of pharmacogenetic testing to inform opioid prescribing for children has evolved with accumulating evidence and guidelines, requiring changes in reporting of results and recommendations.
    MeSH term(s) Humans ; Analgesics, Opioid/adverse effects ; Oxycodone ; Cytochrome P-450 CYP2D6/genetics ; Cytochrome P-450 CYP2D6/metabolism ; Pharmacogenetics/methods ; Practice Patterns, Physicians' ; Codeine/adverse effects ; Chronic Pain/drug therapy
    Chemical Substances Analgesics, Opioid ; Oxycodone (CD35PMG570) ; Cytochrome P-450 CYP2D6 (EC 1.14.14.1) ; Codeine (UX6OWY2V7J)
    Language English
    Publishing date 2024-04-17
    Publishing country England
    Document type Journal Article
    ZDB-ID 1224627-x
    ISSN 1535-2900 ; 1079-2082
    ISSN (online) 1535-2900
    ISSN 1079-2082
    DOI 10.1093/ajhp/zxad025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Biomarkers for antiepileptic drug response.

    Glauser, Tracy A

    Biomarkers in medicine

    2011  Volume 5, Issue 5, Page(s) 635–641

    Abstract: The identification and validation of genetic factors ('biomarkers') that reliably predict the efficacy and toxicity of specific pharmacological agents for individual patients would significantly improve the current treatment of patients with epilepsy. A ... ...

    Abstract The identification and validation of genetic factors ('biomarkers') that reliably predict the efficacy and toxicity of specific pharmacological agents for individual patients would significantly improve the current treatment of patients with epilepsy. A pharmacogenetic biomarker classification has been proposed that identifies three biomarker types involved in drug response: 'known valid biomarkers', 'probable valid biomarkers' and 'exploratory or research biomarkers'. The only known valid antiepileptic drug biomarker is HLA-B*1502 (Stevens-Johnson syndrome in patients of specific Asian backgrounds taking carbamazepine). Probable valid antiepileptic drug biomarkers include polymorphisms in one drug transporter gene, two drug metabolizing genes, three sodium channel genes and one HLA allele. Current methodological challenges to identifying new antiepileptic medication biomarkers can only be overcome with large-scale collaborative research efforts.
    MeSH term(s) ATP Binding Cassette Transporter, Subfamily B ; ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics ; Alleles ; Anticonvulsants/therapeutic use ; Aryl Hydrocarbon Hydroxylases/genetics ; Aryl Hydrocarbon Hydroxylases/physiology ; Biomarkers/metabolism ; Carbamazepine/therapeutic use ; Cytochrome P-450 CYP2C19 ; Cytochrome P-450 CYP2C9 ; Epilepsy/drug therapy ; HLA-A Antigens/genetics ; HLA-B15 Antigen/genetics ; Humans ; Polymorphism, Genetic
    Chemical Substances ABCB1 protein, human ; ATP Binding Cassette Transporter, Subfamily B ; ATP Binding Cassette Transporter, Subfamily B, Member 1 ; Anticonvulsants ; Biomarkers ; HLA-A Antigens ; HLA-A*31:01 antigen ; HLA-B*15:02 antigen ; HLA-B15 Antigen ; Carbamazepine (33CM23913M) ; CYP2C9 protein, human (EC 1.14.13.-) ; Cytochrome P-450 CYP2C9 (EC 1.14.13.-) ; Aryl Hydrocarbon Hydroxylases (EC 1.14.14.1) ; CYP2C19 protein, human (EC 1.14.14.1) ; Cytochrome P-450 CYP2C19 (EC 1.14.14.1)
    Language English
    Publishing date 2011-10-17
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2481014-9
    ISSN 1752-0371 ; 1752-0363
    ISSN (online) 1752-0371
    ISSN 1752-0363
    DOI 10.2217/bmm.11.75
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top